SAN DIEGO, Jan. 24, 2011 /PRNewswire/ — Genelux Corporation, a
privately held, clinical stage biopharmaceutical company developing
diagnostic and therapeutic solutions for cancer and inflammatory
diseases, today announced the appointment of Dr. Dennis Fenton,
long-time Amgen executive, to the company’s Board of Directors. Dr.
Fenton’s appointment expands the Genelux Corporation board to 5
“As someone who helped to build one of the world’s most
successful pharmaceutical companies from the ground up, Dr. Fenton
has a wealth of experience and attributes that will enable him to
make a tremendous contribution to the Genelux Board,” said Aladar
A. Szalay, Founder, Chairman and Chief Executive Officer. “He
brings to this Directorship incredible professional breadth and
depth. A research scientist by training, Dr. Fenton worked in
and led nearly every part of Amgen as it developed, building the
most admired biotechnology manufacturing operation in the world.
I am honored to welcome Dr. Fenton to the Genelux Board as
our second outside Director”.
Dr. Fenton, age 59, retired in December 2007 after 26 years with
Amgen, where he last served as Executive Vice President of
Operations. He was one Amgen’s first employees, joining the
company in 1982 during its first 12 months. Starting as a Research
Scientist, he held positions of increasing responsibility,
including Vice President of Research, Senior Vice President of
Sales and Marketing, Senior Vice President of Operations and was
Amgen’s first Executive Vice President.
Prior to his tenure at Amgen, Dr. Fenton worked for Pfizer
Central research in New Product Development from 1977 until 1981.
Since his retirement from Amgen in 2008, he has been an independent
consultant and a member of several boards including Amira, Kythera,
CytomX, Xenoport, Genzyme, Rutgers University, the Keck Graduate
Institute and the Biotechnology Institute. Dr. Fenton holds a PhD